CN108884097B - 嘧啶类衍生物、其制备方法和其在医药上的用途 - Google Patents

嘧啶类衍生物、其制备方法和其在医药上的用途 Download PDF

Info

Publication number
CN108884097B
CN108884097B CN201780022674.3A CN201780022674A CN108884097B CN 108884097 B CN108884097 B CN 108884097B CN 201780022674 A CN201780022674 A CN 201780022674A CN 108884097 B CN108884097 B CN 108884097B
Authority
CN
China
Prior art keywords
tert
amino
phenyl
dichloro
butoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780022674.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108884097A (zh
Inventor
陈磊
关东亮
白骅
苟俊
赵伟峰
王中利
凌龙
马玉涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd, Shanghai Aryl Pharmtech Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN108884097A publication Critical patent/CN108884097A/zh
Application granted granted Critical
Publication of CN108884097B publication Critical patent/CN108884097B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780022674.3A 2016-05-20 2017-05-19 嘧啶类衍生物、其制备方法和其在医药上的用途 Active CN108884097B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016103414440 2016-05-20
CN201610341444 2016-05-20
PCT/CN2017/085135 WO2017198221A1 (zh) 2016-05-20 2017-05-19 嘧啶类衍生物、其制备方法和其在医药上的用途

Publications (2)

Publication Number Publication Date
CN108884097A CN108884097A (zh) 2018-11-23
CN108884097B true CN108884097B (zh) 2021-05-28

Family

ID=60324797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022674.3A Active CN108884097B (zh) 2016-05-20 2017-05-19 嘧啶类衍生物、其制备方法和其在医药上的用途

Country Status (7)

Country Link
US (4) US10654836B2 (enExample)
EP (1) EP3459952B1 (enExample)
JP (1) JP6667014B2 (enExample)
CN (1) CN108884097B (enExample)
CA (1) CA3024532C (enExample)
TW (1) TWI669300B (enExample)
WO (1) WO2017198221A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
SG10201810057UA (en) 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN108822048A (zh) * 2018-07-23 2018-11-16 上海昌肽生物科技有限公司 4-(4-乙基-4,7二氮杂螺环[3,3]辛基)-2-硝基苯胺的合成工艺
TWI723480B (zh) 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
CN115490670A (zh) * 2021-06-17 2022-12-20 浙江海正药业股份有限公司 Fgfr4选择性抑制剂的盐及其制备方法和用途
CN115504965A (zh) * 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
CN116947825B (zh) * 2022-04-14 2025-11-28 浙江海正药业股份有限公司 Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639510A (zh) * 2009-12-07 2012-08-15 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
AU2013227139B2 (en) * 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
KR20150037207A (ko) * 2013-09-30 2015-04-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리미딘 화합물
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
CN104860891B (zh) * 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639510A (zh) * 2009-12-07 2012-08-15 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors

Also Published As

Publication number Publication date
US11827625B2 (en) 2023-11-28
US20190161476A1 (en) 2019-05-30
EP3459952A4 (en) 2020-01-15
US20210221797A1 (en) 2021-07-22
TWI669300B (zh) 2019-08-21
CN108884097A (zh) 2018-11-23
WO2017198221A1 (zh) 2017-11-23
EP3459952B1 (en) 2022-01-05
US10654836B2 (en) 2020-05-19
TW201741303A (zh) 2017-12-01
JP6667014B2 (ja) 2020-03-18
US12358898B2 (en) 2025-07-15
CA3024532C (en) 2021-02-09
US11001572B2 (en) 2021-05-11
JP2019519512A (ja) 2019-07-11
US20240018130A1 (en) 2024-01-18
US20200207745A1 (en) 2020-07-02
EP3459952A1 (en) 2019-03-27
CA3024532A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
CN108884097B (zh) 嘧啶类衍生物、其制备方法和其在医药上的用途
CN113396147B (zh) 芳香杂环类衍生物调节剂、其制备方法和应用
CN111491920B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN112079830B (zh) 含并环类衍生物抑制剂、其制备方法和应用
CN109311889B (zh) 激活素受体样激酶抑制剂
CN109422755A (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
WO2023025320A1 (zh) 含氮杂环类衍生物抑制剂、其制备方法和应用
JP2016515098A (ja) ブロモドメイン阻害剤として有用なカルバゾール化合物
CN101883774A (zh) 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
KR20160116033A (ko) 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물
WO2021190417A1 (zh) 新型氨基嘧啶类egfr抑制剂
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
TW202321219A (zh) 雜環衍生物及其組合物和藥學上的應用
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN108264511B (zh) 杂环类衍生物及其制备方法和其在医药上的用途
US12404244B2 (en) Pan-KIT kinase inhibitor having quinoline structure and application thereof
CN118373877A (zh) 一种拟肽类降解剂、组合物及其用途
WO2024182689A1 (en) Inhibitors of lrrk2
TW202333715A (zh) 芳雜雙環化合物及其抗病毒用途
WO2025021218A1 (zh) 一种含丙烯酮类生物抑制剂的晶型及其制备方法和应用
EP4539832A2 (en) Phenyl amide compounds and methods of use
US20240262822A1 (en) Wdr5 inhibitors and modulators
CN118666846A (zh) 苯甲羰基吲哚类衍生物及其用途
CN120530094A (zh) Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210422

Address after: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Applicant after: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.

Applicant after: Shanghai Angrui Pharmaceutical Technology Co.,Ltd.

Address before: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Applicant before: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant